Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8)
A phase 1/2 trial of Sunvozertinib, Osimertinib in non-small-cell lung cancer and small-cell lung cancer, run by Dizal Pharmaceuticals, now recruiting.
Overview
Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8) is a phase 1/2 interventional study registered as NCT07079475 by Dizal Pharmaceuticals, with 220 participants planned, started 2025-07-30 and due to reach its primary completion in 2028-06. Interventions recorded: DZD6008, Sunvozertinib, Osimertinib. Conditions listed: Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialAssessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1)
Shares Sunvozertinib, Dizal Pharmaceutical, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialSunvozertinib (DZD9008) in Pretreated Lung Cancer Patients with EGFR Exon20 Insertion Mutation (WU-KONG6)
Shares Sunvozertinib, Dizal Pharmaceutical, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Phase II Clinical Trial of DZD9008 in Combination With AZD4205 in Standard Treatment Failed NSCLC Patients With EGFR Mutations (WU-KONG21)
Shares Sunvozertinib, Dizal Pharmaceutical, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)
Shares Sunvozertinib, Dizal Pharmaceutical, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialDZD9008 In Combination With Bevacizumab in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutation (WU-KONG29)
Shares Sunvozertinib, Dizal Pharmaceutical, Non-small-cell lung cancer.
- TrialA Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Ins
Shares Sunvozertinib, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study to Evaluate Safety and Efficacy of WSD0922-FU Combo With Osimertinib for NSCLC
Shares Osimertinib, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study to Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer (NSCLC)
Shares Osimertinib, Small-cell lung cancer, Non-small-cell lung cancer.